PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications
about
Characterization of two novel cell lines with distinct heterogeneity derived from a single human bile duct carcinomaDetecting non-allelic homologous recombination from high-throughput sequencing data.A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.The role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness: a study in Brazilian patients.Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancerAn immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.Imaging heterogeneity in the mitochondrial redox state of premalignant pancreas in the pancreas-specific PTEN-null transgenic mouse modelThe role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.Caspase control: protagonists of cancer cell apoptosis.Genomic Rearrangements of PTEN in Prostate Cancer.PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis.Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistanceAnalytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.Oncogenes without a Neighboring Tumor-Suppressor Gene Are More Prone to AmplificationBMP2/BMPR1A is linked to tumour progression in dedifferentiated liposarcomas.In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusionPTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles.Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer.Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections.A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.Biomarkers Associated with Tumor Heterogeneity in Prostate Cancer
P2860
Q28485385-03FAE2E2-652A-4C40-84A9-267C0E280969Q30935536-BA38D260-574B-445C-BF91-66D017F123CBQ33739397-4F090EBB-35A7-405B-854C-991191058CF4Q33876961-2B03740A-F788-4743-99B0-52FFD40212A0Q35615320-7911F141-F8DE-4D77-8176-D4C40DEB3096Q36610246-43269954-FA38-4B67-B4F1-931E6237AFB3Q37180312-D0A5ECE0-02E1-4A56-A5DD-DEB7A1A81FE2Q37709925-543B3C43-5D77-4A68-96BB-034B01BEF84FQ38052382-77554064-16E4-42F8-A3F4-D4BC40450E23Q38142173-0B815104-A2F6-4664-8269-60962E774321Q38541293-72050339-459B-4EEB-A497-B3DF4D333FDCQ38797514-A632AD68-F1A2-4E61-B56D-D2E665A40277Q38833458-8F29DC97-62ED-4E5B-A160-2E0EFB21C8C2Q39020973-5FC41CDC-889E-4086-8082-1ECCF351EE8FQ40504792-F1FE2B39-E17E-4327-B576-7C21103870A9Q40919195-74974096-26B1-4F08-B9C7-B2BA109DE428Q40978920-EFCE8B22-6C52-4188-8775-954BFD6F12D1Q41912121-9AC57372-70E7-466C-A88A-9A7AC0794B4FQ42119481-6E7294A7-7B2B-4060-AFCC-50CC5A0A2EEDQ43089446-B1F7FD9B-9816-4993-9808-CC25AAB5F26BQ45359397-B711050D-8C31-4424-8BF1-E70E180CCFFDQ46000712-EB400C2E-4BC4-411D-A24D-1C710C58C64FQ47158122-2A55488A-80D8-4499-BFB1-3CEA653677EBQ47172196-7D1B90D5-70EE-4A9B-8E93-8B7E78DBF2F2Q48231392-CB35AC7A-4977-49F0-991B-536457D45A01Q53842727-C343B84B-9EC5-448B-9B94-4F152FCB2EE8Q58698112-04500725-BE3C-4C7C-9AEA-34DE72CC7B54
P2860
PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications
description
im November 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 November 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2011
@uk
name
PTEN genomic deletions that ch ...... lose to segmental duplications
@en
PTEN genomic deletions that ch ...... lose to segmental duplications
@nl
type
label
PTEN genomic deletions that ch ...... lose to segmental duplications
@en
PTEN genomic deletions that ch ...... lose to segmental duplications
@nl
prefLabel
PTEN genomic deletions that ch ...... lose to segmental duplications
@en
PTEN genomic deletions that ch ...... lose to segmental duplications
@nl
P2093
P2860
P356
P1476
PTEN genomic deletions that ch ...... lose to segmental duplications
@en
P2093
Andrew Evans
Dave DeGrace
Julia L Williams
Kanishka Sircar
Maisa Yoshimoto
Olga Ludkovski
Paulo Nuin
Tarek A Bismar
P2860
P304
P356
10.1002/GCC.20939
P577
2011-11-01T00:00:00Z